Biolidics
Singapore, Singapore· Est.
Innovative Singapore diagnostics firm delivering label‑free CTC enrichment and rapid COVID‑19 test kits.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $10M
AI Company Overview
Innovative Singapore diagnostics firm delivering label‑free CTC enrichment and rapid COVID‑19 test kits.
OncologyInfectious Disease
Technology Platform
Patented microfluidic biochip (CTChip® FR1) enables label‑free, automated enrichment of viable circulating tumour cells; rapid immunoassay kits detect SARS‑CoV‑2 antigens and neutralising antibodies.
Opportunities
Expansion of the CTC platform into companion‑diagnostic markets and broader adoption of rapid COVID‑19 testing; leveraging digital lifestyle ventures for diversified revenue.
Risk Factors
Regulatory hurdles for new diagnostics, intense competition from established liquid‑biopsy providers, and execution risk associated with diversification into non‑core businesses.
Competitive Landscape
Competes with CellSearch (Veridex), CTC‑Chip, and other liquid‑biopsy firms; differentiates through label‑free, viable CTC isolation and an integrated, automated workflow.